The power to assess potential outcomes and intervention strategies is critical for epidemic preparedness. But emerging and mutated pathogens always challenge our current knowledge, pleading for fresh approaches to explore their epidemic potentials up front.
This paper coupled a within-host viral dynamics model and a between-host network model of Ebola virus (EBOV) infection showing that its transmission characteristics can be faithfully recapitulated.
Based on this multiscale model, EBOV's incubation period is predicted in the range from 2.6 to 12.4 days, while infected subjects can remain infectious until day 17. The predicted basic reproductive number (R0) differs by age-groups: the overall is 1.4 and the highest is 4.7 for the 10-14 years old. Random vaccination strategies can reduce R0 and case-fatality rate, eliminate the possibility of large outbreaks, but the effect depends on timing and coverage.
A random vaccination program can reduce R0 below one if 85% coverage is achieved, and if it was conducted during the period from five months before to one week after the start of an epidemic. A vaccination coverage of 33% can reduce the epidemic size by ten to hundred times compared to a non-intervention scenario. Altogether, infection characteristics and epidemic mitigation approaches could be assessed using experimental data. An early, age-group specific, and high coverage vaccination program is the most beneficial.
these key processes in the disease transmission are lost, especially the transient nature of the 16 infection course [9] . In reality, the within-host infection process determines key parameters in individual(s) that eventually lead to a transmission, depending on both the infectivity of the infectious and the susceptibility of the susceptible. 17 the disease transmission [9] [10] [11] [12] [13] . In an infected subject, interactions between the viruses and (NHPs) are the standard animal model for developing EBOV's therapeutics and vaccines in 48 humans [28, 29] which recently has been used to develop an effective vaccine against EBOV 49 [30] . Epidemiological and pharmacological studies reported that a viral load higher than 50 10 6 copies/mL [29, 31] is associated with a higher mortality rate, whereas observations on 51 experimental data in NHPs showed that a viral load level higher than 10 6 TCID 50 was fatal 52 [24, 25] . Here the viral load dynamics were simulated based on the model as follows [13] :
where r V , K V and In denote the replication rate, the host's carrying capacity, and a constraint 55 threshold expressing the lag-phase growth of the virus. The parameter K Ab represents the 56 strength of the immune system at which the antibody titre inhibits the viral net growth rate [13] .
57
The model parameters were obtained previously [13] using two experimental datasets on NHPs 58 [24, 25] . The antibody dynamic (Ab) was fitted previously [13] to data of NHPs vaccinated with 59 vesicular stomatitis virus (VSV-EBOV) vaccine [25] . The VSV-EBOV has recently showed efficacy 60 in human [30] . Detailed of model fitting and data can be found in [13] .
61
Simulated subject-specific infection course 62 To simulate subject-specific infection course, the antibody response strength K Ab was varied 63 from a normal level approximately 10 2.5 [25, 32] to the highest observed level of 10 4.5 [25] .
64
This value was assumed to vary based on individual's age, i.e., a U-shaped function of age 65 with larger values for the infant and the elderly [15] . As infective dose can alter the course of 66 infection [33] , the initial condition V (0) of model Eq. (1.1) was varied depending on from whom a 67 subject acquires the infection, i.e., equals the lethal dose (Vc = 10 0.15 [13] ) times the transmission 68 potential of whom transmits the disease. Here we assumed a direct relation [10] between the 69 transmission potential and the viral load at the time of infection, i.e., the transmission potential 70 p Trans (t) = V (t)/K V . Note that p Trans (t) = 1 does not guarantee a successful transmission, but 71 it was considered collectively with its contacts susceptibility and with the existence of such a 72 contact. 
Measure Definition
A Incubation period the interval between exposure to a pathogen and initial occurrence of symptoms [4] was defined from the infection time to the first time the viral load crosses over the detectable threshold (Fig. S2) . B
Time from symptom onset to recovery [4] defined as the interval between the first day of detectable viral load and the first day the viral load goes undetectable (Fig. S2 ). C Time from symptom onset to death [4] defined as the interval between the first day with detectable viral load and the day the area under the viral load curve (AUC) crosses the reference threshold AU C 7 (Fig. S2 ). D Basic reproductive number (R0) calculated based on the network of infected subjects at the end of an epidemic. In terms of network models, this equals the mean degree distribution of the infected network, considering a directed network without loops (e.g., Fig. S3 ). The R0 by age-group was also calculated in the same fashion based on the assigned age-attribute.
Note that in epidemics with intervention, the R0 is called the effective reproductive number (Re). E Final infected fraction the proportion of infected nodes at the end of the epidemic simulations. F Case-fatality rate the proportion of nodes died as a result of EBOV infection calculated as the end of epidemics.
Infection outcomes definitions 74
Empirical observations from both EBOV infected human and NHPs showed that the time from 75 symptom onset to death is approximately one week [24, 25, 34] . Based on this and the viral load, 76 we used the total area under the viral load curve (AUC) seven days post-infection in the subjects 77 that died as a threshold above which the infection is lethal, i.e., AUC 7 = 7 0 V (t)dt. Otherwise, 78 infected subjects were assumed recovered once the viral load was no longer detectable ( Fig. S2 ).
79
Depending on the infective dose and the adaptive immune response strength, an infection will 80 manifest different viral dynamics. Based on that, we defined the transmission parameters as in 81 Table 1A -C.
82
The network model 83 The European's contact patterns survey data [35] were used to generate a network model Simulations of the outcomes of the within-host infection model showed a highly skewed 111 distribution of the basic transmission parameters (Fig. 2) . The incubation period derived from (median: 9) compared to previous estimates ranged from 3 to 21 (median: 9-10) [4] .
117
Basic reproductive number (R0) 118 Simulation results showed that the overall estimate of the R0 was 1.43 (Fig. 3) . However, the 119 estimates differed by age-groups with the highest of 4.7 for the group of 10-14 years of age.
120
Generally, the age-groups with a higher contact rate had also a higher R0. Simulations of 121 epidemics with varied intervention strategies showed that the Re can be reduced below one 122 if the vaccination program with 85% coverage were deployed as far as five months before the introduction of the index case (time zero) or as late as one week after that (Fig. S4 ). This coverage 124 threshold was tested as it is the highest vaccine coverage currently achieved worldwide for some A synthetic population of ten thousand individuals was generated. One thousand simulations were run to simulate the epidemic in the time course of one year. Each time, one individual was chosen randomly as the index case. Circles, diamonds, and connected lines are median. Filled areas are the corresponding non-parametric densities estimates [41] .
Two median values are presented for multi-modal density estimates, determining by inflection points. size (Fig. 4) . The two points epidemics size distribution gradually converged to a uni-modal 
